secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001493152-25-022318
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem posts Q3 2025 operating income of $1.0M; net sales up 10% YoY to $5.0M
-----------------------------------------------------------------------------

- Net sales $5.0M in Q3 2025 vs $4.5M Q3 2024; operating income $1.0M vs loss of $2.4M.
- Net loss attributable to common stockholders $1.7M ($0.01 per share) vs $2.4M ($0.02) prior year.
- Total operating expenses decreased 42% to $4.0M, helped by $1.9M gain from change in Rush royalty estimate.
- Terminated merger with Aditxt after stockholders did not approve the deal at Oct 20 special meeting.
- Advancing manufacturing cost reduction targeting ~50% lower COGS for both PHEXX and SOLOSEC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315225022318/0001493152-25-022318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315225022318/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-022318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer